Those price targets DO NOT account for nearly 60 million of newly printed shares in 2021, so those price targets are closer to $3. I dont know why the analyst dont want to use the updated floats. Guess they already burned so many clients they want to have a higher target. They know the intelligent investor can do the updated math. Good luck to the ignorant.
$SRGA pending FDA approval for its revolutionary digital surgery platform. Very few competitors in the field, insiders buying significantly in the month of Aug., the company posted number of job postings in the last couple of weeks and strong management with more than 20 years of expertise in this field. 6 Analysists with "buy" ratings and price target of $4. I know I've invested in a good company is just a matter of time.
View original message